Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Stopped Phase 2 of recruitment was contingent on 5 of 15 patients responding, which did not occur.

Conditions

• Breast Cancer

Interventions

• DRUG: Everolimus

Sponsor

Yale University

Collaborators

• [object Object]